The current delay in intervention is likely related to a limited understanding of the disease pathophysiology ... anticoagulation may be initiated for 1–3 months, if the risk of thrombosis is high.

TAT and several other markers demonstrated an ability to predict the development of venous thromboembolism in patients with cervical cancer.

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...